Henning Stennicke

Henning Stennicke serves as the Chief Scientific Officer at Spur Therapeutics since March 2022, bringing extensive experience from previous roles at Novo Nordisk spanning two decades, including Senior Principal Scientist and Corporate Project Vice President positions in various sectors such as Biopharm and Haemophilia. Additionally, Henning contributes as a Board Member at atSpiro. Academic credentials include a Ph.D. in Biochemistry from the University of Copenhagen and an eMBA in Business Administration and Management from the Technical University of Denmark, supplemented by executive education at Harvard Business School, Copenhagen Business School, and The Wharton School. Prior roles include Senior Scientist at Rigshospitalet and Postdoctoral Fellow at The Burnham Institute.